215 related articles for article (PubMed ID: 16032439)
1. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.
Lambert B; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):980-9. PubMed ID: 16032439
[TBL] [Abstract][Full Text] [Related]
2. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide therapy of hepatocellular carcinoma.
Keng GH; Sundram FX
Ann Acad Med Singap; 2003 Jul; 32(4):518-24. PubMed ID: 12968558
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study.
Brans B; De Winter F; Defreyne L; Troisi R; Vanlangenhove P; Van Vlierberghe H; Lambert B; Praet M; de Hemptinne B; Dierckx RA
Cancer Biother Radiopharm; 2001 Aug; 16(4):333-8. PubMed ID: 11603004
[TBL] [Abstract][Full Text] [Related]
5. Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials.
Zeng ZC; Tang ZY; Liu KD; Lu JZ; Xie H; Yao Z
J Cancer Res Clin Oncol; 1998; 124(5):275-80. PubMed ID: 9645459
[TBL] [Abstract][Full Text] [Related]
6. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up.
Ahmadzadehfar H; Habibi E; Ezziddin S; Wilhelm K; Fimmers R; Spengler U; Palmedo H; Strunk H; Schild HH; Biersack HJ; Risse J
Nuklearmedizin; 2014; 53(2):46-53. PubMed ID: 24468919
[TBL] [Abstract][Full Text] [Related]
7. Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment.
Wu L; Shen F; Xia Y; Yang YF
Anticancer Agents Med Chem; 2016; 16(9):1155-65. PubMed ID: 26961314
[TBL] [Abstract][Full Text] [Related]
8. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours.
Lambert B; Bacher K; Defreyne L
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):305-10. PubMed ID: 19521309
[TBL] [Abstract][Full Text] [Related]
9. 131-iodine Lipiodol therapy in hepatocellular carcinoma.
Raoul JL; Boucher E; Roland V; Garin E
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315
[TBL] [Abstract][Full Text] [Related]
10. Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 131I-Lipiodol delivery on tumour uptake and response.
Brans B; Bacher K; Vandevyver V; Vanlangenhove P; Smeets P; Thierens H; Dierckx RA; Defreyne L
Nucl Med Commun; 2003 Apr; 24(4):391-6. PubMed ID: 12673167
[TBL] [Abstract][Full Text] [Related]
11. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
[TBL] [Abstract][Full Text] [Related]
12. Effect of a 188 Re-SSS lipiodol/131I-lipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma.
Garin E; Rakotonirina H; Lejeune F; Denizot B; Roux J; Noiret N; Mesbah H; Herry JY; Bourguet P; Lejeune JJ
Nucl Med Commun; 2006 Apr; 27(4):363-9. PubMed ID: 16531923
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
[TBL] [Abstract][Full Text] [Related]
14. Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol.
Kanhere HA; Leopardi LN; Fischer L; Kitchener MI; Maddern GJ
ANZ J Surg; 2008 May; 78(5):371-6. PubMed ID: 18380736
[TBL] [Abstract][Full Text] [Related]
15. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil.
Kumar A; Srivastava DN; Bal C
J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146
[TBL] [Abstract][Full Text] [Related]
16. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
[TBL] [Abstract][Full Text] [Related]
17. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy.
Lambert B; de Klerk JM
Nucl Med Commun; 2006 Mar; 27(3):223-9. PubMed ID: 16479241
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
Stipsanelli E; Valsamaki P
Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome.
Lambert B; Praet M; Vanlangenhove P; Troisi R; de Hemptinne B; Gemmel F; Van Vlierberghe H; Van de Wiele C
Cancer Biother Radiopharm; 2005 Apr; 20(2):209-14. PubMed ID: 15869457
[TBL] [Abstract][Full Text] [Related]
20. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol.
Raoul JL; Messner M; Boucher E; Bretagne JF; Campion JP; Boudjema K
Br J Surg; 2003 Nov; 90(11):1379-83. PubMed ID: 14598418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
